Program
HR17031
A development code. Also written as “HR17031 injection” and “HR17031 injection ;INS068 injection;SHR20004 injection”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 70 open or running | phase 3since Feb 26, 2025 | Aug 16, 2021 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HR17031
, phase 4, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2021First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05031871 · 24 enrolled · China
- Dec 7, 2021Phase 1 study in Improved Glycemic Control in Patients With Type 2 DiabetesNCT05151705 · 24 enrolled
- Mar 15, 2022Phase 1 study in Improved Glycemic Control in Patients With Type 2 DiabetesNCT05292495 · 24 enrolled · China
- Apr 12, 2022Phase 2 study in Diabetes Mellitus, Type 2NCT05333835 · 455 enrolled · China
- Oct 12, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT06086912 · 24 enrolled · China
- Feb 26, 2025Phase 3 study in Adult Patients With Type 2 DiabetesNCT06871761 · 393 enrolled · China
- Mar 12, 2025Phase 3 study in Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic DrugsNCT06881264 · 401 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06881264Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs · China | 3 | Completed | Sep 19, 2025 | 401 |
| NCT06871761Adult Patients With Type 2 Diabetes · China | 3 | Completed | May 13, 2025 | 393 |
| NCT06086912Diabetes Mellitus, Type 2 · China | 1 | Completed | Dec 12, 2023 | 24 |
| NCT05333835Diabetes Mellitus, Type 2 · China | 2 | UNKNOWN | Mar 30, 2024 | 455 |
| NCT05292495Improved Glycemic Control in Patients With Type 2 Diabetes · China | 1 | Completed | Apr 10, 2024 | 24 |
| NCT05151705Improved Glycemic Control in Patients With Type 2 Diabetes | 1 | UNKNOWN | Jun 15, 2022 | 24 |
| NCT05031871Diabetes Mellitus, Type 2 · China | 1 | Completed | Nov 19, 2021 | 24 |
How it is read
Names in the registry
- “HR17031 injection”, 7 entries
- “HR17031 injection ;INS068 injection;SHR20004 injection”, 4 entries
- “HR17031”, 3 entries
Codes read as this program: HR17031.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.